1560 TRAPELO ROAD, WALTHAM, MA
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Annual Report to Security Holders
Financial Results, Press Release
Investor Presentation
Vikram Karnani Elected as Class II Director of Dyne Therapeutics
Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities